Company Cash Funds: Alterity Therapeutics Ltd (ATHE)

Anticipation of the Phase II trial results for the Parkinson's disease drug is driving the current trend for Alterity Therapeutics (ATHE), while the market has already priced in the lack of profit. Free cash flow reflects current liquidity, with the metric standing at 0.03. Alterity Therapeutics (ATHE) is deploying capital toward R&D without generating cash flow; however, scientific management is persistently attracting investment to combat rare neurodegenerative pathologies.
Summary analytical data breakdowns for Alterity Therapeutics Limited (ATHE)

This indicator measures the actual balance of liquid assets, allowing the investor to calculate the burn rate and identify hidden cash gaps between reporting periods. By analyzing the cash on hand, one can assess the ability of Alterity Therapeutics (ATHE) to fund costly outsourced clinical trials amidst a heavy reliance on third-party laboratories and regulatory constraints.